Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

PHASE2RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

July 23, 2024

Primary Completion Date

March 4, 2026

Study Completion Date

December 24, 2027

Conditions
B Precursor Acute Lymphoblastic LeukemiaRelapsed/Refractory B Precursor Acute Lymphoblastic Leukemia
Interventions
DRUG

Blinatumomab

Administered via CIVI

Trial Locations (6)

200127

RECRUITING

Shanghai Children's Medical Center, Shanghai

215002

RECRUITING

Children's Hospital of Soochow University, Suzhou

230601

RECRUITING

The Second Hospital of Anhui Medical University, Hefei

300020

RECRUITING

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin

400015

RECRUITING

Childrens Hospital of Chongqing Medical University, Chongqing

510280

RECRUITING

Zhujiang Hospital of Southern Medical University, Guangzhou

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY